U.S. markets close in 1 hour 38 minutes

Adaptimmune Therapeutics plc (ADAP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.0321+0.0221 (+0.73%)
As of 02:20PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close3.0100
Bid3.0300 x 2900
Ask3.0400 x 1000
Day's Range3.0000 - 3.1203
52 Week Range3.0000 - 7.3400
Avg. Volume857,548
Market Cap473.626M
Beta (5Y Monthly)1.93
PE Ratio (TTM)N/A
EPS (TTM)-1.0020
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.17
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ADAP

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Adaptimmune Therapeutics plc
    Daily – Vickers Top Buyers & Sellers for 01/18/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • Motley Fool

    2 Cancer Stocks With Absurdly Low Valuations

    The potential for four or more interest rate hikes by the Federal Reserve over the course of 2022 has been weighing heavily on growth stocks of late. Investors are clearly pivoting toward safe havens like value and dividend stocks ahead of this perceived eventuality. Shares of the cancer specialists Adaptimmune Therapeutics (NASDAQ: ADAP) and Clovis Oncology (NASDAQ: CLVS) are both trading at absurdly low valuations following their steep downturns over the past several weeks.

  • Zacks

    4 Biotechs That Could Be Potential Takeover Targets in 2022

    We discuss a few companies like BioMarin (BMRN), Adaptimmune (ADAP), CRISPR Therapeutics (CRSP), and Alnylam Pharmaceuticals (ALNY) with solid product portfolios, deep pipelines which make them attractive candidates for a potential takeover in 2022.

  • Motley Fool

    Here's Why Biotech Stocks Adaptimmune Therapeutics, Agenus, and Ocugen All Crashed in November

    A mix of marketwide headwinds and company-specific events weighed on these three biotech stocks in November.